Trends In Uncertainties And Outcomes Following An Assessment Of Cancer Topic Suitability For The Cancer Drugs Fund - read online free

Sep 29, 2026

Uploaded by Theodore

Assesses how changes to NICE health technology assessment (HTA) methods in 2022 and the publication of a national commercial framework affected recommendation outcomes for cancer medicines considered for the Cancer Drugs Fund (CDF). NICE staff recorded evidence-uncertainty types across cancer topics from 2016–2024 and linked them to outcomes such as CDF entry, full reimbursement, optimized-population reimbursement, no reimbursement, or research-only. Findings show stable uncertainty trends with a modest increase overall, alongside declining CDF entries.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

OP60 National Horizon Scanning System In Brazil: Current Actions And Outputs Ana Carolina de Freitas Lopes, Thais Conceição Borges, Aramis Tupiná Alcântara de Moreira, Karine Medeiros Amaral, Munique Gonçalves Guimaraes, Viviane Del Lama Cardoso Salas, Barbara Pozzi Ottavio and Luciene Bonan ([luciene.bonan@saude.gov.br](luciene.bonan@saude.gov.br)) Introduction: Horizon scanning (HS) initiatives in Brazil began in 2008 . Since then, the implementation of a national HS system has shown great evolution and expansion, especially after the creation of the National Committee for Health Technology Incorporation (CONITEC), which absorbed it in 2011 . This work aimed to present Brazil’s National Horizon Scanning System, conducted by CONITEC, and its most recent results. Methods: We developed an experience report, using mixed methods, with a descriptive analysis of HS activities conducted nationally and quantification of documents produced between December 2023 and November 2024 by CONITEC. Results: HS reports developed by CONITEC currently support the decision-making processes regarding the: (i) incorporation of technologies into the public health system (90 reports); (ii) granting of new or emerging technologies by court order (five alerts);(iii) prioritization of topics for the elaboration or update of national clinical practice guides (28topics); (iv) national preparation incase of public health emergencies (e.g., COVID-19 and mpox) (two documents); (v) innovation and national development (five brief syntheses); and (vi) financing of research with health technologies (one document) . Conclusions: The implementation of a national HS system in Brazil has evolved significantly and today it represents an important source of evidence that supports strategic decisions for Brazil’s public health system. From December 2023 to November 2024, CONITEC produced 131 HS studies to support decision-making in six different processes within the public health system. OP62 Trends In Uncertainties And Outcomes Following An Assessment Of Cancer Topic Suitability For The Cancer Drugs Fund Sarika Paul ([sarika.paul@nice.org.uk](sarika.paul@nice.org.uk)), Leanne Wakefield, Catrin Austin, Milena Wobbe, Steve Norton, Robert Fernley and Steve Williamson Introduction: The Cancer Drugs Fund (CDF) is a type of managed entry agreement used in England to allow patient access while undertaking evidence generation followed by re-evaluation to address uncertainty. We assessed the impact of changes to the National Institute for Health and Care Excellence (NICE) health technology assessment (HTA) methods in 2022 plus the publication of a national commercial framework on recommendation outcomes. Methods: NICE staff, in conjunction with clinical stakeholders, assess all cancer medicines for their suitability for entry into the CDF. Cancer topics looked at by NICE from 2016 to 2024 were identified, and the type of evidence uncertainties and the final recommendation outcomes were recorded. Types of evidence uncertainty were assigned to one of nine different categories: survival data, relevant patient population, lack of relevant comparators, trial design, quality-of-life data, cost estimates, treatment duration, costeffectiveness model, and adverse events. Recommendation outcomes included entry to the CDF, full reimbursement, reimbursement for optimized population, no reimbursement, or research only. Results: The types of uncertainties identified for appraisals using pre-2022 methods (n=103) and post-2022 methods (n=35) showed the same trends in most common uncertainties. Immature survival data was the most common, with lack of relevant comparators the second most common. There was an increase in the average number of uncertainties seen in post-2022 topics (2.05), compared with pre-2022 topics (1.75) . The number of CDF recommendations has been decreasing in recent years, with a peak between 2017 and 2019 . For appraisals that did not enter the

FAQs

What is the Cancer Drugs Fund (CDF) and how does it work?

The CDF is a managed entry agreement in England that allows patient access while evidence is generated, followed by re-evaluation to address uncertainty.

How were evidence uncertainties classified in the assessment?

Uncertainty types were assigned to nine categories, including immature survival data, lack of relevant comparators, trial design, quality-of-life data, cost estimates, treatment duration, cost-effectiveness model, and adverse events.

What were the main changes observed after the 2022 NICE methods update?

No clear change appeared in the overall trends of uncertainties, though overall uncertainty increased slightly. CDF entries declined, aligning with a more flexible commercial environment and alternative reimbursement options.

Sep 29, 2026

Uploaded by Theodore